Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions
Chondrocalcinosis
Interventions
DRUG

Colchicine opocalcium 1mg

"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."

DRUG

Prednisone : Cortancyl 20mg

"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."

Trial Locations (7)

59000

CHRU Lille, Lille

59240

Dr Rémi LEROY, Dunkirk

59280

Dr Nicolas SEGAUD, Armentières

59322

CH Valenciennes, Valenciennes

59462

Lille Catholic Hospital, Lille

75010

Hôpital de Lariboisière, Paris

75018

Hôpital Bichat, Paris

All Listed Sponsors
collaborator

University Hospital, Lille

OTHER

collaborator

Hopital Lariboisière

OTHER

collaborator

Bichat Hospital

OTHER

collaborator

Valenciennes Hospital Centre

UNKNOWN

collaborator

Armentières Hospital Centre

UNKNOWN

collaborator

Dunkerque Hospital Centre

UNKNOWN

lead

Lille Catholic University

OTHER

NCT03128905 - Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis | Biotech Hunter | Biotech Hunter